06/02/2026
Researchers at UCLA Jonsson Comprehensive Cancer Center found that drug selpercatinib can reduce the risk of lung cancer returning in patients with a rare subtype of early-stage non-small cell lung cancer. This could offer a new treatment option.
Selpercatinib, a highly selective, potent, and central nervous system–penetrant rearranged during transfection (RET) inhibitor, is approved for RET fusion–positive advanced or metastatic non–small-...